Drug intelligence / Profile preview

P276

Development stage: Phase 2
Lead developer: Piramal
Modality: Small Molecules
Administration: Oral

Overview

P276 is a code name referring to a small molecule cyclin-dependent kinase (CDK) inhibitor, specifically P276-00, developed as an anticancer agent. The drug was designed to inhibit cyclin D1/CDK4 and CDK9, which are involved in cell cycle regulation and transcription. P276 has been evaluated in preclinical and early clinical studies for various solid tumors and hematological malignancies. It works by blocking the phosphorylation of the retinoblastoma protein and inhibiting transcription of key survival-related genes, thereby inducing growth arrest and apoptosis in cancer cells.

Other names: P276-00P-276-00P 276-00riviciclib hydrochloride

Targets

P-TEFb (Positive transcription elongation factor b)CDK4 (Cyclin-dependent kinase 4)CDK1 (Cyclin-dependent kinase 1)

Beyond the preview

Go deeper on P276.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on P276.

Explore the full profile